首页> 中文期刊> 《实用医院临床杂志》 >常规治疗基础上14肽生长抑素联合大承气汤治疗重症急性胰腺炎疗效观察

常规治疗基础上14肽生长抑素联合大承气汤治疗重症急性胰腺炎疗效观察

         

摘要

目的 评价常规治疗基础上14肽生长抑素(商品名:施他宁)联合大承气汤治疗重症急性胰腺炎(acute severity pancreatitis,SAP)的疗效.方法 常规治疗基础上采用14肽生长抑素和大承气汤口服治疗26例SAP患者(观察组),并与同期未用大承气汤治疗的25例SAP患者(对照组)比较,观察两组治疗第1、3、5天急性生理和慢性健康状况评分Ⅱ(APACHE Ⅱ),以及血清淀粉酶、尿淀粉酶的变化;腹痛、腹胀等主要临床症状、体征改善情况及住院天数、并发症发生率、中转手术率和死亡率.结果 两组并发症发生率、手术率、死亡率、禁食、腹痛、腹胀时间及住院天数比较,差异均有统计学意义(P<0.05).结论 常规治疗基础上采用14肽生长抑素和大承气汤口服治疗SAP具有良好的效果.%Objective To evaluate the therapeutic effect of 14-peptide somatostatin (Stilamin) and Da Cheng Qi Tang by feeding and enema for severe acute pancreatitis (SAP). Methods Twenty-six patients with SAP received traditional treatment in combination with 14-peptide somatostatin and Da Cheng Qi Tang, and were compared with 25 SAP patients with routine treatment The changes of acute physiology and chronic health evaluation II , serum amylase, urinary amylase, improvement of the main clinical symptoms and signs such as abdominal pain and abdominal distention, hospital stay, complications, operation rate and mortality on the 1st, 3rd and 5th day were compared between two groups. Results There were significant differences between the two groups in complications, operation rate, mortality, fast, duration of abdominal pain and abdominal distention, and hospital stay (/><0. 05). Conclusions The combination of 14-peptide somatostatin and Da Cheng Qi Tang is effective in the treatment of SAP patients.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号